The abstract is read at the publisher; the summary is JClub's.
After neoadjuvant therapy for muscle-invasive bladder cancer, radical cystectomy remains standard because clinical complete response matches true pathological complete response only about half the time.
- Why it matters: Restaging tools cannot reliably identify patients truly disease-free, and bladder preservation strategies using systemic therapy alone have shown concerning recurrence and metastasis rates.
- What they did: The review synthesizes evidence from neoadjuvant regimens with high pathological complete response rates (NIAGRA, KEYNOTE-B15/905) and bladder preservation trials (RETAIN-1/2, HCRN GU 16-257), plus early-phase trimodal radiation approaches (IMMUNOPRESERVE, INDIBLADE).
- The result: Until validated biomarkers and prospective trials demonstrate otherwise, cystectomy should remain within the curative-intent treatment paradigm for muscle-invasive bladder cancer.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.